Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

Adil Daud, MD
Published: Monday, Aug 28, 2017



Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Immunotherapy is at a very exciting point in melanoma, says Daud. Specifically, there were a number of combinations presented at the 2017 ASCO Annual Meeting for the relapse/refractory population that showed responses.
 


Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Immunotherapy is at a very exciting point in melanoma, says Daud. Specifically, there were a number of combinations presented at the 2017 ASCO Annual Meeting for the relapse/refractory population that showed responses.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x